Glycaemic control with advanced new insulins for the treatment of diabetes
DOI:
https://doi.org/10.1002/edn.56Keywords:
Insulin, Exubera, analogues, diabetesAbstract
AbstractThe benefits of maintaining blood glucose levels as near normal as possible are well appreciated. The advent of insulins with varying rates of onset and duration of action has made it possible to closely mimic normal physiological glycaemic control.
This review considers advances in insulin therapy with attention focussed on the most recently introduced rapid-acting insulin analogue glulisine (Apidra®) and the novel inhaled insulin Exubera®.
Downloads
References
The Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–986.
Stratton IM, Adler AT, Neil HAW, et aL Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observa-tional study. BMJ 2000; 321: 405–412.
Nathan DM, Buse JB, Davidson MB, et aL Management of hypergly-caemia in type 2 diabetes: a consen-sus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006; 49: 1711–1721; Diabetes Care 2006; 29: 1963-1972.
Feher MD, Bailey CJ. Reclassifying insulins. Br J Diabetes Vasc Dis 2004; 4: 39–42.
Krentz AJ, Bailey CJ. Type 2 diabetes in practice. London: Royal Society of Medicine Press, 2005; 206.
Bailey CJ, Feher MD. Therapies for diabetes. Birmingham: Sherborne Gibbs Ltd, 2004; 127.
Day C, Archer H, Bailey CJ. Recent advances in insulin therapy. Br J Cardiol 2003; 10: 379–383.
Brown H. Needle-free insulin. Br J Diabetes Vasc Dis 2004; 4: 113–115.
Skyler J. Pulmonary insulin: current status. Diabetes Voice 2006; 51: 23–25.
Bellary S, Barnett AH. Inhaled insulin: overcoming barriers to insulin therapy. Br J Diabetes Vasc Dis 2006; 6: 103–108.
Exubera SmPC http://www.emea.eu.int/humandocs/PDFs/EPAR/exubera/H-588-PI-en.pdf#search=%22exubera%20package%20insert%22 [Accessed August 2006].
Exubera website. http://www.exubera.com/content/download_medguide.jsp [Accessed August 2006].
Patton JS, Bukar JG, Eldon MA. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 2004; 43: 781–801.
Heinemann L, Traut T, Heise T. Time-action profile of inhaled insulin. Diabet Med 1997; 14: 63–72.
Rave K, Bott S, Heinnemann L, et aL Time-action profile of inhaled insulin in comparison with subcuta-neously injected insulin lispro and regular human insulin. Diabetes Care 2005; 28: 1077–1082.
Rosenstock J, Cappelleri JC, Bolinder B, et aL Patient satisfaction and glycaemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 dia-betes. Diabetes Care 2004; 27: 1318–1323.
Freemantle N, Blonde L, Duhot D, et aL. Availability of inhaled insulin promotes greater perceived accept-ance of insulin therapy in patients with type 2 diabetes. Diabetes Care 2005; 28: 427–428.
Generextrial abstracts. http://www.generex.com/products/oral-lyn/clinical_highlights.asp [Accessed August 2006].
Shojaee-Moradie F, Powrie JK, Sundermann E, et al. Novel hepatos-elective analog studies with a cova-lently linked thyroxl-insulin com-plex in humans. Diabetes Care 2000; 23: 1124–1129.
Worrall DS, McDunn JE, List B, et aL. Synthesis of an organo-insulin mole-cule that can be activated by anti-body catalysis. Proc Natl Acad Sci USA 2001; 98: 13514–13518.
Saljoughian M. New advances in dia-betes treatment. US Pharm 2005; 6: H52–H59.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2006 Copyright © 2006 FEND.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
